BACKGROUND: The aim of this study was to establish the prevalence of erectile dysfunction (ED) in hypertensive patients in specialized care hypertension units (SCHUs) and to assess the effectiveness and tolerability of sildenafil treatment. METHODS: This was a multicenter, prospective, open, observational pharmacoepidemiology study conducted in 25 Spanish SCHUs. A total of 2130 men with essential hypertension under treatment were recruited. In a second phase, 291 subjects with a score < or = 21 in the Sexual Health Inventory for Men (SHIM) received sildenafil (50 mg/day) as required 30 to 60 minutes before sexual activity, and were evaluated by the International Index of Erectile Function (IIEF). RESULTS: A total of 975 subjects (45.8%) had a score < or = 21 in the SHIM. In the second phase, sildenafil improved the score in the erectile function domain in 232 patients (83.2%). Severity of ED significantly improved (P <.001); severe (22.3% to 7.7%), moderate (23% to 5.6%), and mild impairment (36.3% to 44.8%). The IIEF was normalized in 39.1% of patients who completed post-treatment IIEF. In all, 33 subjects (11.8%) failed to complete the study: two (0.7%) because of lack of efficacy, two (0.7%) intercurrent disease, 10 (3.6%) failure to return to the visits, three (1.1%) fear of therapy, four (1.4%) adverse effects requiring treatment discontinuation, and 12 (4.3%) protocol violations. No statistically significant association was found between the prevalence of adverse effects and antihypertensive treatment with single drug or combination therapy. CONCLUSIONS: A high incidence of ED was found in hypertensive patients from Spanish SCHUs. Sildenafil showed an excellent response and safety profile.
BACKGROUND: The aim of this study was to establish the prevalence of erectile dysfunction (ED) in hypertensivepatients in specialized care hypertension units (SCHUs) and to assess the effectiveness and tolerability of sildenafil treatment. METHODS: This was a multicenter, prospective, open, observational pharmacoepidemiology study conducted in 25 Spanish SCHUs. A total of 2130 men with essential hypertension under treatment were recruited. In a second phase, 291 subjects with a score < or = 21 in the Sexual Health Inventory for Men (SHIM) received sildenafil (50 mg/day) as required 30 to 60 minutes before sexual activity, and were evaluated by the International Index of Erectile Function (IIEF). RESULTS: A total of 975 subjects (45.8%) had a score < or = 21 in the SHIM. In the second phase, sildenafil improved the score in the erectile function domain in 232 patients (83.2%). Severity of ED significantly improved (P <.001); severe (22.3% to 7.7%), moderate (23% to 5.6%), and mild impairment (36.3% to 44.8%). The IIEF was normalized in 39.1% of patients who completed post-treatment IIEF. In all, 33 subjects (11.8%) failed to complete the study: two (0.7%) because of lack of efficacy, two (0.7%) intercurrent disease, 10 (3.6%) failure to return to the visits, three (1.1%) fear of therapy, four (1.4%) adverse effects requiring treatment discontinuation, and 12 (4.3%) protocol violations. No statistically significant association was found between the prevalence of adverse effects and antihypertensive treatment with single drug or combination therapy. CONCLUSIONS: A high incidence of ED was found in hypertensivepatients from Spanish SCHUs. Sildenafil showed an excellent response and safety profile.
Authors: Mariacristina Vecchio; Sankar D Navaneethan; David W Johnson; Giuseppe Lucisano; Giusi Graziano; Marialuisa Querques; Valeria Saglimbene; Marinella Ruospo; Carmen Bonifati; Emmanuele A Jannini; Giovanni F M Strippoli Journal: Clin J Am Soc Nephrol Date: 2010-05-24 Impact factor: 8.237
Authors: Chingching Foocharoen; Alan Tyndall; Eric Hachulla; Edoardo Rosato; Yannick Allanore; Dominique Farge-Bancel; Paola Caramaschi; Paolo Airó; Starovojtova M Nikolaevna; José António Pereira da Silva; Bojana Stamenkovic; Gabriela Riemekasten; Simona Rednic; Jean Sibilia; Piotr Wiland; Ingo Tarner; Vanessa Smith; Anna T Onken; Walid Ahmed Abdel Atty Mohamed; Oliver Distler; Jadranka Morović-Vergles; Andrea Himsel; Paloma Garcia de la Peña Lefebvre; Thomas Hügle; Ulrich A Walker Journal: Arthritis Res Ther Date: 2012-02-20 Impact factor: 5.156
Authors: Shobana Navaneethabalakrishnan; Bethany L Goodlett; Alexandra H Lopez; Joseph M Rutkowski; Brett M Mitchell Journal: Clin Sci (Lond) Date: 2020-12-23 Impact factor: 6.876